Stock message boards
MNV
Market News Video
MNV MNV 10 Bargains You Can Buy Cheaper Than Insiders Did
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Commit To Purchase Thoratec At $31, Earn 11% Annualized Using Options
Friday, January 16, 1:39 PM ET, by Market News Video Staff

Investors considering a purchase of Thoratec Corp. (THOR) shares, but tentative about paying the going ...

Top Buys by Directors: Neal's $498.4K Bet on JPM
Tuesday, January 20, 1:00 PM ET, by Market News Video Staff

The directors of a company tend to have a unique inside view into the business, ...

Interesting JPM Put And Call Options For May 15th
Tuesday, January 20, 1:01 PM ET, by Market News Video Staff

Investors in JPMorgan Chase & Co (JPM) saw new options become available today, for the ...

JPMorgan Chase & Co Named Top Dividend Stock With Insider Buying and 2.87% Yield (JPM)
Tuesday, January 20, 2:08 PM ET, by Market News Video Staff

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then ...

First Week of LF September 18th Options Trading
Wednesday, January 21, 12:32 PM ET, by Market News Video Staff

Investors in Leapfrog Enterprises Inc (LF) saw new options become available this week, for the ...

  More articles:  1 2 3 4 5 6 7 next »

Today's Big Losers: LF, THOR

By Market News Video Staff, Wednesday, January 12, 3:26 PM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Educational toy maker LeapFrog Enterprises (NYSE:LF) lowered its full-year earnings forecast due to reduced demand for its toys during the holidays.

The company forecast both sales and earnings below estimates. The company now forecasts sales to increase 13-14 percent for the full year, or $433 million, below estimates of $452.3 million and growth of 15-20 percent. Full-year earnings are forecast to be 3-6 cents a share, below analyst expectations of 28 cents a share.

The stock is trading lower by over 22.5 percent.

Thoratec (NASDAQ:THOR) shares are lower on Wednesday after following a lackluster presentation at the JP Morgan (NYSE:JPM) Healthcare Conference. Following the conference, JP Morgan reiterated its "neutral" rating on the stock, and gave it a $30 price target.

Shares are lower by over 6.8 percent.


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Conference   Definition   Definitions   Earnings   Enterprises   Following   Market   Morgan   NYSE   Price   Relevant   Share   Stock   THOR   Wednesday   after   analyst   below   both   cents   company   earnings   estimates   expectations   following   forecast   forecasts   full   gave   holidays   lackluster   lower   lowered   maker   million   neutral   over   percent   presentation   price   rating   reiterated   sales   share   shares   stock   target   toys   trading   year
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Today's Big Losers: LF, THOR | Market News Video | Copyright © 2008 - 2015, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.